New cancer drug BR111 enters first human trial
NCT ID NCT06937957
First seen Nov 21, 2025 · Last updated May 16, 2026 · Updated 25 times
Summary
This early-stage study tests a new drug called BR111 in 166 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find the safest dose and to see if the drug can shrink tumors. Participants receive the drug every three weeks, and researchers will monitor side effects, how the drug moves through the body, and the immune response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Cancer
RECRUITINGShanghai, Pudong New Area, No. 4333, Kangxin Road, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.